PACRA has awarded Martin Dow Marker Limited Pakistan (the Company) an A+ long-term rating and an A1 short-term rating with a stable outlook.
Martin Dow Marker Limited is a well-known name in Pakistan’s pharmaceutical sector, having been in operation since 1951. The Company is a subsidiary of the Martin Dow Group, one of the largest locally-owned pharmaceutical conglomerates.
Mr. Javed Ghulam Mohammad, Group Managing Director & CEO of Martin Dow, stated following the announcement, “With an uninterrupted legacy spanning over half a century, the Martin Dow Group is benchmarked for delivering quality products that continue to improve the health of millions of people worldwide.” We are happy to have received an A+ long-term credit rating and an A1 short-term credit rating from PACRA, demonstrating our operations’ excellent standards.”
The Company’s portfolio is diverse, and it has a sizable manufacturing footprint in Pakistan. It commercialises research-based pharmaceuticals through strategic relationships with global pharmaceutical companies and through the sale of world-class branded generics created, formulated, and manufactured at its state-of-the-art cGMP-compliant manufacturing facilities in Quetta and Karachi. The Company has developed an exceptional growth profile over the years and has positioned itself among the industry’s top ten leading pharmaceutical companies.
The Company operates sustainably and has an aggressive growth strategy that includes the introduction of new technologies and products and geographic expansion through the export of pharmaceutical products from Pakistan.
Martin Dow Group is a significant multinational healthcare conglomerate in Pakistan with a global footprint that promotes over 100 brands and employs over 3000 people across the country.
